Loss of mitochondrial aconitase promotes colorectal cancer progression via SCD1-mediated lipid remodeling

Xin You,Jingyu Tian,Hui Zhang,Yunhua Guo,Jing Yang,Chaofeng Zhu,Ming Song,Peng Wang,Zexian Liu,John Cancilla,Wenhua Lu,Christophe Glorieux,Shijun Wen,Hongli Du,Peng Huang,Yumin Hu
DOI: https://doi.org/10.1016/j.molmet.2021.101203
IF: 8.568
2021-06-01
Molecular Metabolism
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>The mitochondrial aconitase (ACO2) is an essential enzyme that bridges TCA cycle and lipid metabolism. However, its role in cancer development remains to be elucidated. The metabolic subtype of colorectal cancer (CRC) has recently been established. We aim to investigate the potential role of ACO2 in CRC progression through mediating metabolic alterations.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We compared the mRNA and protein expression of ACO2 between paired CRC and non-tumor tissues from 353 patients. Correlation between ACO2 level and clinicopathological features was examined. CRC cell lines with knockdown or overexpression of ACO2 were analyzed for cell proliferation and tumor growth. Metabolomics and stable isotope tracing analysis were used to study the metabolic alterations induced by loss of ACO2.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>ACO2 was decreased in &gt;50% of CRC samples compared with matched non-tumor tissues. Decreased ACO2 level was correlated with advanced disease stage (<em>P</em>&lt;0.001) and shorter patient survival (<em>P</em>&lt;0.001). Knockdown of ACO2 in CRC cells promoted cell proliferation and tumor formation, while ectopic expression of ACO2 restrained tumor growth. Specifically, blockade of ACO2 caused reduction in TCA cycle intermediates and suppression of mitochondrial oxidative phosphorylation, resulting in increase of glycolysis and elevated citrate flux for fatty acid and lipid synthesis. Increased citrate flux was able to induce upregulation of stearoyl-CoA desaturase (SCD1), which enhanced lipid desaturation in ACO2-deficent cells to favor colorectal cancer growth. Pharmacological inhibition of SCD selectively reduced tumor formation of CRC with ACO2 deficiency.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Our study uncovers the rewiring metabolic pathway to maintain CRC survival during compromised TCA cycle and characterizes the therapeutic vulnerability of lipid desaturation in a meaningful subset of CRC with mitochondrial dysfunction.</p>
endocrinology & metabolism
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the role of mitochondrial aconitase (ACO2) in the progression of colorectal cancer (CRC) and its impact on tumor development by mediating metabolic changes. Specifically, the research aims to: 1. **Clarify the expression changes of ACO2 in CRC**: By comparing the mRNA and protein expression levels of ACO2 in CRC tissues and non - tumor tissues, explore the down - regulation of ACO2 in CRC. 2. **Analyze the relationship between ACO2 levels and clinicopathological features**: Study the association between ACO2 levels and the clinical stage, survival time, etc. of CRC patients. 3. **Evaluate the impact of ACO2 on CRC cell proliferation and tumor growth**: By knocking down or over - expressing ACO2, observe its impact on CRC cell proliferation and tumor formation. 4. **Explore the metabolic reprogramming caused by ACO2 deletion**: Using metabolomics and stable isotope tracer techniques, analyze the impact of ACO2 deletion on the tricarboxylic acid (TCA) cycle, oxidative phosphorylation, glycolysis and lipid synthesis. 5. **Reveal the importance of lipid desaturation in ACO2 - deleted CRC**: Study how ACO2 deletion promotes lipid desaturation by up - regulating stearoyl - CoA desaturase (SCD1), thereby supporting the growth of CRC, and explore the therapeutic potential of inhibiting SCD1. Through these studies, the paper hopes to provide new insights into the metabolic mechanisms of CRC and potential targets for treatment strategies targeting metabolic pathways.